Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions.
WHY WE'RE FUNDRAISING WITH THE JIMMY FUND WALK TO FIGHT CANCER
Kimberly Perez, MD, is a physician-scientist at Dana-Farber Cancer Institute where she treats patients and conducts clinical research of novel therapies for patients diagnosed with gastrointestinal cancers and associated hereditary cancer syndromes. She treats patients in the Gastrointestinal Cancer Center and in the Center for Cancer Genetics and Prevention’s High-Risk Clinic. She specializes in neuroendocrine and carcinoid tumors as well as pancreatic cancers and is a researcher within the Program in Neuroendocrine and Carcinoid Tumors.
Dr. Perez’s research is focused on neuroendocrine tumors (NETs), hereditary cancer syndromes, and clinical trial development. She is leading a research study aimed at defining the percentage of NET cases that are hereditary vs. random by defining the prevalence of hereditary (germline) genes mutations in NET. Preliminary data shows 5-10% of NET have mutations in hereditable genes.
Ongoing clinical trials led by Dr. Perez include:
- She is studying the role of immunotherapy, therapies that harness the body’s immune system to attack cancer, in treating NET. Currently she is leading a trial evaluating a combination of immunotherapy (nivolumab) and cabozantinib for NET patients.
- She has led several clinical trials for patients with advanced (metastatic) pancreatic adenocarcinoma as a member of the Hale Family Center for Pancreatic Cancer.
- She is collaborating with colleagues at the National Institute of Health and the Alliance for Clinical Protocol to develop the first clinical trial analyzing the role of the inherited mutations in clinical outcomes in patients with advanced pheochromocytomas (PHEOs) and paragangliomas (PGLs)—rare NETs—treated with temozolomide (chemotherapy) and olaparib (targeted therapy).
Your philanthropy will fuel Dr. Perez’s work to develop better treatments and prevent these cancers. Thank you for your generosity.
To contribute by check, please write "Dr. Perez’s Giving Page" in memo line, and send to:
Dana-Farber Cancer Institute
Attn: Giving Pages
10 Brookline Place West, 6th Floor
Brookline, MA 02445
617-632-6247
Dr. Perez earned her undergraduate degree from Georgetown University and her Doctor of Medicine from George Washington University School of Medicine. She completed a residency in internal medicine and fellowships in hematology and oncology at Rhode Island Hospital and The Miriam Hospital. She lives in Rhode Island with her husband, two children, and dog.
THANK YOU TO OUR TEAM MEMBERS
= Team CaptainBE THE FIRST TO GIVE!
